Wall Street brokerages expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report $5.30 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Seres Therapeutics’ earnings, with the lowest sales estimate coming in at $2.50 million and the highest estimate coming in at $8.73 million. Seres Therapeutics posted sales of $8.19 million during the same quarter last year, which suggests a negative year over year growth rate of 35.3%. The business is expected to report its next quarterly earnings report on Thursday, May 6th.

On average, analysts expect that Seres Therapeutics will report full-year sales of $159.56 million for the current year, with estimates ranging from $10.00 million to $695.80 million. For the next fiscal year, analysts expect that the firm will report sales of $56.24 million, with estimates ranging from $12.00 million to $106.01 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Monday, March 1st. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.05. Seres Therapeutics had a negative net margin of 385.22% and a negative return on equity of 2,867.98%.

A number of equities research analysts have commented on MCRB shares. Chardan Capital raised Seres Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $27.50 to $30.00 in a report on Thursday, March 11th. Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 25th. JMP Securities began coverage on Seres Therapeutics in a research note on Wednesday, December 23rd. They issued a “market perform” rating on the stock. Finally, Oppenheimer reissued a “buy” rating and set a $38.00 price target on shares of Seres Therapeutics in a research report on Tuesday, March 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Seres Therapeutics presently has a consensus rating of “Buy” and an average price target of $33.43.

Shares of Seres Therapeutics stock opened at $19.74 on Thursday. The firm has a market capitalization of $1.81 billion, a P/E ratio of -16.87 and a beta of 4.07. Seres Therapeutics has a 52 week low of $3.08 and a 52 week high of $38.50. The firm’s 50 day moving average is $20.62 and its two-hundred day moving average is $26.08. The company has a quick ratio of 6.73, a current ratio of 6.73 and a debt-to-equity ratio of 0.13.

A number of institutional investors and hedge funds have recently modified their holdings of MCRB. Price T Rowe Associates Inc. MD grew its stake in Seres Therapeutics by 223.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,883,260 shares of the biotechnology company’s stock worth $46,140,000 after buying an additional 1,301,109 shares during the last quarter. Lord Abbett & CO. LLC grew its stake in Seres Therapeutics by 313.7% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,327,897 shares of the biotechnology company’s stock worth $32,533,000 after buying an additional 1,006,953 shares during the last quarter. Janus Henderson Group PLC grew its stake in Seres Therapeutics by 38.2% during the 4th quarter. Janus Henderson Group PLC now owns 2,645,274 shares of the biotechnology company’s stock worth $64,810,000 after buying an additional 731,197 shares during the last quarter. State of Michigan Retirement System bought a new position in Seres Therapeutics during the 4th quarter worth $8,823,000. Finally, Sumitomo Mitsui Trust Holdings Inc. grew its stake in Seres Therapeutics by 5.3% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,823,603 shares of the biotechnology company’s stock worth $142,678,000 after buying an additional 291,933 shares during the last quarter. Hedge funds and other institutional investors own 94.32% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

See Also: Why is the ex-dividend date different from the record date?

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.